{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T20:21:42Z","timestamp":1770409302544,"version":"3.49.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2001,10,1]],"date-time":"2001-10-01T00:00:00Z","timestamp":1001894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2001,10]]},"DOI":"10.1067\/mhj.2001.117317","type":"journal-article","created":{"date-parts":[[2002,8,24]],"date-time":"2002-08-24T18:14:26Z","timestamp":1030212866000},"page":"590-593","source":"Crossref","is-referenced-by-count":24,"title":["Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?"],"prefix":"10.1067","volume":"142","author":[{"given":"Timothy D.","family":"Henry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Satran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorri L.","family":"Knox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl L.","family":"Iacarella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David D.","family":"Laxson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elliott M.","family":"Antman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1067\/mhj.2001.117317_bib1","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","article-title":"A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease","volume":"337","author":"Cohen","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2001.117317_bib2","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.100.15.1593","article-title":"Enoxaparin prevents death and cardiac ischemic events in unstable angina\/non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11B Trial","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"10.1067\/mhj.2001.117317_bib3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1053\/pcad.2000.0420235","article-title":"The emerging role of low-molecular-weight heparin in cardiovascular medicine","volume":"42","author":"Hirsch","year":"2000","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1067\/mhj.2001.117317_bib4","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJM199709043371007","article-title":"Low-molecular-weight heparins","volume":"337","author":"Weitz","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2001.117317_bib5","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/0735-1097(94)90636-X","article-title":"Comparison of Hemochron and HemoTec activated coagulation time target values during percutaneous transluminal coronary angioplasty","volume":"23","author":"Avendano","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"10.1067\/mhj.2001.117317_bib6","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/0735-1097(94)90590-8","article-title":"Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty","volume":"23","author":"Ferguson","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"10.1067\/mhj.2001.117317_bib7","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0735-1097(97)00094-6","volume":"29","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1067\/mhj.2001.117317_bib8","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S0002-9149(99)00582-2","article-title":"Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris","volume":"84","author":"Rabah","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1067\/mhj.2001.117317_bib9","doi-asserted-by":"crossref","first-page":"S577","DOI":"10.1053\/hj.1999.v138.a102299","article-title":"The emerging role of low-molecular-weight heparin and antiplatelet therapies in the cardiac catheterization laboratory","volume":"138","author":"Deutsch","year":"1999","journal-title":"Am Heart J"},{"key":"10.1067\/mhj.2001.117317_bib10","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/01.CIR.103.5.658","article-title":"Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris","volume":"103","author":"Collet","year":"2001","journal-title":"Circulation"},{"key":"10.1067\/mhj.2001.117317_bib11","first-page":"272","article-title":"Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention","volume":"13","author":"Kereiakes","year":"2001","journal-title":"J Invasive Cardiol"},{"issue":"suppl E","key":"10.1067\/mhj.2001.117317_bib12","first-page":"E10","article-title":"Combining low-molecular-weight heparin and glycoprotein 11b\/11Ia antagonists for the treatment of acute coronary syndromes: the NICE 3 story","volume":"12","author":"Ferguson","year":"2000","journal-title":"J Invasive Cardiol"},{"issue":"suppl E","key":"10.1067\/mhj.2001.117317_bib13","first-page":"E5","article-title":"Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein 11b\/11Ia blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes","volume":"12","author":"Cohen","year":"2000","journal-title":"J Invasive Cardiol"},{"key":"10.1067\/mhj.2001.117317_bib14","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1213\/00000539-200009000-00006","article-title":"A quick anti-Xa-activity-based whole blood coagulation assay for monitoring unfractionated heparin during cardiopulmonary bypass: a pilot investigation","volume":"91","author":"Hansen","year":"2000","journal-title":"Anesth Analg"},{"key":"10.1067\/mhj.2001.117317_bib15","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1161\/01.CIR.102.17.2051","article-title":"Novel, bedside, tissue factor-dependent clotting assay permits improved assessment of combination antithrombotic and antiplatelet therapy","volume":"102","author":"Holmes","year":"2000","journal-title":"Circulation"},{"key":"10.1067\/mhj.2001.117317_bib16","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1055\/s-0037-1614377","article-title":"Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: interassay variability","volume":"82","author":"Kitchen","year":"1999","journal-title":"Thromb Haemost"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870301136331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870301136331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,15]],"date-time":"2019-12-15T21:25:00Z","timestamp":1576445100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870301136331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,10]]}},"alternative-id":["S0002870301136331"],"URL":"https:\/\/doi.org\/10.1067\/mhj.2001.117317","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2001,10]]}}}